CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 10,756,235	$ 15,215,285
Accounts receivable, net of allowance of $75,000 and $330,853 at June 30, 2023 and September 30, 2022, respectively	682,701	3,067,544
Inventories	276,422	602,244
Prepaid expenses and other current assets	524,904	1,058,056
Total current assets	12,240,262	19,943,129
Property and equipment, net	1,168,038	2,222,988
Other assets:
Restricted cash	750,000
Capitalized transaction costs	275,726
Operating right of use asset	1,355,508
Deposits		98,997
Total assets	15,789,534	22,265,114
Current liabilities:
Accounts payable and accrued liabilities	2,127,908	3,621,751
Operating lease liability, current	487,425
Deferred revenue	275,885	563,557
Total current liabilities	2,891,218	4,185,308
Long term accrued liabilities	31,467	31,467
Operating lease liability, long term	868,081
Warrants classified as a liability	4,804,700	5,139,400
Total liabilities	8,595,466	9,356,175
Commitments and contingencies
Applied DNA Sciences, Inc. stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30 2023 and September 30, 2022, respectively
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of June 30, 2023 and September 30, 2022, 12,908,520 shares issued and outstanding as of June 30, 2023, 2023 and September 30, 2022	12,909	12,909
Additional paid in capital	306,091,402	305,399,008
Accumulated deficit	(298,854,883)	(292,500,088)
Applied DNA Sciences, Inc. stockholders' equity	7,249,428	12,911,829
Noncontrolling interest	(55,360)	(2,890)
Total equity	7,194,068	12,908,939
Total liabilities and equity	15,789,534	22,265,114
Series A Preferred stock
Applied DNA Sciences, Inc. stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30 2023 and September 30, 2022, respectively
Series B Preferred stock
Applied DNA Sciences, Inc. stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30 2023 and September 30, 2022, respectively